Title
Category
Credits
Event date
Cost
Screening and Accurate Diagnosis of Patients With Bipolar Disorder Type I and Type II
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Drs Goldberg, Swartz, and DelBello discuss the spectrum of bipolar disorder, from major depressive disorder to bipolar I, and assessment strategies for establishing accurate diagnoses, including age, gender, signs and symptoms, and comorbidities to facilitate appropriate treatments and improve patient outcomes.
Treatment Options for Bipolar I and Bipolar II Disorder
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
As novel agents join the treatment landscape for bipolar I and bipolar II disorder and new data emerge on existing therapeutics, clinicians need education on the latest evidence of the safety and efficacy profiles of existing and emerging treatments for bipolar I and bipolar II disorder. Join Drs Goldberg, DelBello, and Swartz in examining how to integrate this information into clinical practice and provide efficacious and tolerable treatment for patients with bipolar I and bipolar II disorder.
Acute and Maintenance Treatment Strategies for Bipolar Depression: the Focus on Bipolar Depression Type I and Type II
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Treating bipolar I and bipolar II depression is not one-size-fits-all. Learn from field experts about practice guidelines, novel agents, and approaches to developing personalized treatment plans for patients with bipolar depression type I and type II.
Communicating With Patients and Families: Sharing the Treatment Journey of Bipolar Disorder
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Dr Goldberg describes the role of the clinician as that of a travel agent, asking the patient, “Where do you want to go; what do you want it to be like there; how do you want to get there;” etc, then providing the patient with the related evidence-supported information. Learn how to become your patients’ travel agent for their journey through optimizing treatment strategies for type I and type II bipolar disorder.
Acute and Maintenance Treatment Strategies for Bipolar I: Focus on Mixed and Manic Episodes
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Adopting consensus guidelines while applying new evidence on the latest treatment options can often be a matter of balancing risks, benefits, and tolerability when addressing acute episodes in bipolar I disorder. Sit in on the discussion between three experts as they discuss guideline-directed treatment strategies that address manic and mixed episodes in patients with bipolar I disorder, and listen to one patient’s journey to hope and recovery.
Therapeutic Tolerability and Adherence in Bipolar Disorder
  • Bipolar Disorder
  • Bipolar Depression
  • Depression
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Involving patients in designing their own treatment strategies according to their tolerability criteria can help combat the 90% nonadherence rate in patients being treated for bipolar disorder. Find out from experts about best practices in addressing patient concerns and balancing tolerability with efficacy and adherence in treating patients with bipolar disorder.
Impact of Cannabis Use, Substance Use Disorders, and Psychiatric Diagnoses on COVID-19 Outcomes: A Retrospective Cohort Study
  • Psychotic Disorders
  • Substance Use Disorders
  • COVID-19
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation
$0.00
Identifying risk factors that predispose individuals to negative COVID-19 outcomes is important. The current study examined the association between substance use disorders, psychiatric diagnosis, and COVID-19–related clinical outcomes.
Mild Cognitive Impairment Due to Alzheimer Disease
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Diagnostic Tools
  • Education
  • Functional Impairment
  • Geriatric Psychiatry
  • Neuroimaging
  • Neurology
  • Patient/Physician Communication
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Drs Anderson and Malone discuss the burden of, signs and symptoms of, diagnostic tools and criteria for mild cognitive impairment (MCI) and mild/early dementia and the benefits of early diagnosis. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
Differentiating and Treating Alzheimer’s Disease
  • Alzheimer Disease
  • Cognition
  • Dementia
  • Diagnostic Tools
  • Education
  • Functional Impairment
  • Geriatric Psychiatry
  • Neuroimaging
  • Neurology
  • Patient/Physician Communication
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
$0.00
Drs Anderson and Malone cover the types of dementia and their indicators, ways to approach care for mild cognitive impairment (MCI) and mild dementia, and treatment options available or in the pipeline for disease intervention. Early diagnosis and intervention of MCI and mild dementia can slow disease progression and optimize outcomes for both patients and caregivers.
Tweetorial: Long COVID in Children and Adolescents
  • Child and Adolescent Psychiatry
  • COVID-19
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Participation
$0.00
Long COVID symptoms are both physical and mental in nature among children and adolescents and have the potential to affect long-term functioning and increase the overall burden on health care delivery.

Pages